DMAC
DiaMedica Therapeutics Inc
NASDAQ: DMAC · HEALTHCARE · BIOTECHNOLOGY
$6.05
+1.51% today
Updated 2026-04-30
Market cap
$341.08M
P/E ratio
—
P/S ratio
66.68x
EPS (TTM)
$-0.70
Dividend yield
—
52W range
$3 – $10
Volume
0.2M
DiaMedica Therapeutics Inc (DMAC) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
7 of 8
Last 8 quarters
Avg EPS surprise
+2.0%
Last 4 quarters
Revenue YoY growth
-100.2%
Most recent quarter
EPS YoY growth
+5.6%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-9.2%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-15.2%
2025-11-12
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-31 | $-0.17 | +2.9% | $6.64 | $6.42 | -3.3% |
| 2025-11-12 | $-0.17 | +0.0% | $6.39 | $5.42 | -15.2% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.18 | $-0.17 | +2.9% | $-27999.00 | -100.2% |
| 2025-09-30 | $-0.17 | $-0.17 | +0.0% | — | — |
| 2025-06-30 | $-0.19 | $-0.18 | +5.3% | — | — |
| 2025-03-31 | $-0.18 | $-0.18 | +0.0% | — | — |
| 2024-12-31 | $-0.17 | $-0.18 | -4.3% | $13.80M | -55.2% |
| 2024-09-30 | $-0.15 | $-0.15 | +0.0% | — | — |
| 2024-06-30 | $-0.16 | $-0.13 | +18.8% | — | — |
| 2024-03-31 | $-0.16 | $-0.14 | +12.5% | — | — |
| 2023-12-31 | $-0.14 | $-0.14 | +0.0% | $30.84M | — |
| 2023-09-30 | $-0.13 | $-0.12 | +7.7% | — | — |
| 2023-06-30 | $-0.18 | $-0.16 | +11.1% | — | — |
| 2023-03-31 | $-0.16 | $-0.20 | -25.0% | — | — |
Frequently asked questions
Has DiaMedica Therapeutics Inc beaten earnings estimates?
DiaMedica Therapeutics Inc has beaten Wall Street EPS estimates in 7 of its last 8 quarterly reports, with an average EPS surprise of +2.0% over the last 4 quarters.
How does DMAC stock react to earnings?
DMAC stock has moved an average of -9.2% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is DiaMedica Therapeutics Inc's revenue growth rate?
DiaMedica Therapeutics Inc reported year-over-year revenue growth of -100.2% in its most recent quarter, with EPS growing +5.6% year-over-year.